In an indication with few treatment options for patients who are running out of time, Replimune Group Inc. revealed positive top-line results of its lead candidate, RP-1 (vusolimogene oderparepvec), in anti-PD-1-failed melanoma. Data from the phase I/II Ignyte study of RP-1 plus Opdivo (nivolumab, Bristol Myers Squibb Co.) showed the treatment hit the primary endpoint with a 12-month overall response rate of 33.6% and a median duration of response of more than 35 months.
Arrivent Biopharma Inc. and Jiangsu Alphamab Biopharmaceuticals Co. Ltd. have signed a development deal that leverages Alphamab’s antibody-drug conjugate (ADC) research and discovery platform and could bring Alphamab up to $615.5 million.
Isotope Technologies Munich SE (ITM) raised €188 million ($204 million) in a funding round that will largely be used to advance and expand the company’s radiopharmaceutical pipeline. The funds, which come a year after ITM raised €255 million, are a sign of growing investor interest in the company’s products and the radiopharma market, Steffen Schuster, CEO of ITM, told BioWorld.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described serine/threonine-protein kinase ULK1 inhibitors reported to be useful for the treatment of cancer.
Scientists at Korea Research Institute of Chemical Technology and Oncord Bio Inc. have divulged molecular glue degraders targeting protein cereblon (CRBN) and acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer, graft-vs.-host disease, leprosy and inflammatory disorders.
Nikang Therapeutics Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 2 (CDK2) targeting moiety through a linker reported to be useful for the treatment of cancer.
Ribometrix Inc. has synthesized eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and allergy.
Relay Therapeutics Inc. has disclosed three new programs from its existing preclinical pipeline, including two novel programs from its genetic disease portfolio and a potentially first-in-class NRAS-selective inhibitor.
KRAS is the most commonly mutated oncogene in solid tumors. Mutations are present in about 30% of cases overall, more than 95% of pancreatic cancer cases, and about 40% of colon cancer cases.
Nutcracker Therapeutics Inc. has disclosed a new drug candidate for the treatment of B-cell lymphoma – NTX-472 – along with results from in vivo studies performed to evaluate its efficacy in mice and macaques.
RSS
